We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Immunochromatographic Test Detects Fecal Parasites

By LabMedica International staff writers
Posted on 15 Feb 2012
A recently developed test that detects three pathogenic protozoal parasites in human stool samples has been evaluated. More...


An immunochromatographic (IC) dip strip test simultaneously detects Cryptosporidium spp, Giardia duodenalis, and Entamoeba histolytica that are known to cause diarrheal disease.

At the University of Zaragoza (Spain) scientists collected 160 stool samples from patients with intestinal discomfort or diarrhea, in which parasitic infections needed to be ruled out. Samples were taken and analyzed by microscopic examination and by different IC tests, from July 2008 to December 2008. Fresh specimens were processed within 24 hours of collection. Besides the IC tests, both enzyme-linked immunosorbent assays (ELISA) and heminested polymerase chain reactions (PCR) were performed. Microscopy and PCR were the “gold standard” reference techniques and the results of the RidaQuick IC triple stool test were compared with those obtained with ELISA and IC single test for the three parasites.

Microscopic examination revealed that 22 samples were diagnosed as positive for Cryptosporidium spp., 31 for Giardia duodenalis, 41 for Entamoeba histolytica/dispar, and 68 had a negative diagnosis for the three parasites. Results of RidaQuick IC tests (R-Biopharm; Darmstadt, Germany) show sensitivities of 70%-72% for Cryptosporidium, 90%-97% for Giardia and 62.5% for Entamoeba histolytica. Specificities for these three protozoa were 93.6%-94.9%, greater than 99% and 96.1%, respectively. In all diagnoses, agreement with microscopy and PCR was over 90%, except in the triple test and microscopy in E. histolytica detection that was 76.3%, due to the inability of microscopy to differentiate E. histolytica from nonpathogenic species such as E. dispar or E. moshkovskii.

The authors concluded that the triple stool immunoassays provide adequate sensitivities and specificities with clinically relevant cost-effectiveness. They can be used in outbreak situations, for screening proposals and for massive assays in endemic areas where a large number of samples must be analyzed or as complementary test for individual diagnosis since the entire test could be performed in 15–20 minutes. The study was published online on January 20, 2012, in the Journal of Clinical Microbiology & Infectious Diseases.

Related Links:

University of Zaragoza
R-Biopharm



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.